Showing results (411-420 of 534) with videos related to

Sort By:
Pageof 54
American Journal of Hematology|September 19, 2022
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesDaniel Rivera, Kunhwa Kim, Rashmi Kanagal-Shamanna, et al.
JCO Precision Oncology|May 17, 2023
Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class RearrangementsJayastu Senapati, Elias Jabbour, Marina Konopleva, et al.
Blood Advances|December 19, 2023
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclaxAlex Bataller, Alexandre Bazinet, Courtney D DiNardo, et al.
American Journal of Hematology|January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agentsElias Jabbour, Paolo Strati, Monica Cabrero, et al.
Cancers|November 27, 2024
Cladribine-Based Therapy for Acute Myeloid Leukemia in Child, Adolescent, and Early Young Adult Patients: The MD Anderson Cancer Center ExperienceDavid McCall, Shaikha Alqahtani, Moriah Budak, et al.
Nature Communications|October 13, 2019
Contribution of retrotransposition to developmental disordersEugene J Gardner, Elena Prigmore, Giuseppe Gallone, et al.
JNCI Cancer Spectrum|June 27, 2025
Risk of early death after acute leukemia diagnosis among adolescents and young adultsAmy M Berkman, Clark R Andersen, Vidya Puthenpura, et al.
Blood Advances|December 4, 2024
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapyWei-Ying Jen, Koji Sasaki, Farhad Ravandi, et al.
Journal of Hematology & Oncology|May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemiaHagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Haematologica|October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitorNicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
Pageof 54